Home  »  Business   »  Investor Trust Slackened After Sutro Biopharma Inc...

Investor Trust Slackened After Sutro Biopharma Inc. (NASDAQ: STRO) Shares Gained By $0.03

Sutro Biopharma Inc. (NASDAQ:STRO) has a beta value of 0.92 and has seen 0.43 million shares traded in the recent trading session. The company, currently valued at $407.76M, closed the recent trade at $7.57 per share which meant it gained $0.03 on the day or 0.46% during that session. The STRO stock price is -45.05% off its 52-week high price of $10.98 and 56.01% above the 52-week low of $3.33. If we look at the company’s 10-day average daily trading volume, we find that it stood at 0.88 million shares traded. The 3-month trading volume is 587.92K shares.

Sutro Biopharma Inc. (NASDAQ:STRO) trade information

Sporting 0.46% in the green today, the stock has traded in the red over the last five days, with the highest price hit on Monday, 01/23/23 when the STRO stock price touched $7.57 or saw a rise of 3.57%. Year-to-date, Sutro Biopharma Inc. shares have moved -6.68%, while the 5-day performance has seen it change -4.19%. Over the past 30 days, the shares of Sutro Biopharma Inc. (NASDAQ:STRO) have changed 12.87%. Short interest in the company has seen 1.95 million shares shorted with days to cover at 2.73.

Will You Miss Out On This Growth Stock Boom?

A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.

And this is just one of our 5 Best Growth Stocks To Own For 2023.


Sutro Biopharma Inc. (STRO) estimates and forecasts

Figures show that Sutro Biopharma Inc. shares have underperformed across the wider relevant industry. The company’s shares have gained 25.04% over the past 6 months, with this year growth rate of -23.30%, compared to 4.50% for the industry. Other than that, the company has, however, lowered its growth outlook for the 2023 fiscal year revenue. Growth estimates for the current quarter are -10.40% and 4.80% for the next quarter. Revenue growth from the last financial year stood is estimated to be -16.50%.

6 analysts offering their estimates for the company have set an average revenue estimate of $12.68 million for the current quarter. 8 have an estimated revenue figure of $10.18 million for the next quarter concluding in Dec 2022. Year-ago sales stood $8.97 million and $10.65 million respectively for this quarter and the next, and analysts expect sales will grow by 41.40% for the current quarter and -4.40% for the next.

STRO Dividends

Sutro Biopharma Inc. is expected to release its next earnings report between March 06 and March 13 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.

Sutro Biopharma Inc. (NASDAQ:STRO)’s Major holders

Insiders own 7.00% of the company shares, while shares held by institutions stand at 92.35% with a share float percentage of 99.30%. Investors are also buoyed by the number of investors in a company, with Sutro Biopharma Inc. having a total of 181 institutions that hold shares in the company. The top two institutional holders are Suvretta Capital Management, LLC with over 4.64 million shares worth more than $24.2 million. As of Jun 29, 2022, Suvretta Capital Management, LLC held 8.91% of shares outstanding.

The other major institutional holder is Franklin Resources, Inc., with the holding of over 3.77 million shares as of Jun 29, 2022. The firm’s total holdings are worth over $19.66 million and represent 7.24% of shares outstanding.

Also the top two Mutual Funds that are holding company’s shares are Mutual Fund Ser Tr-Eventide Healthcare & Life Sciences Fund and Vanguard Total Stock Market Index Fund. As of Jun 29, 2022, the former fund manager holds about 5.19% shares in the company for having 2.71 million shares of worth $14.11 million while later fund manager owns 1.19 million shares of worth $6.2 million as of Jun 29, 2022, which makes it owner of about 2.28% of company’s outstanding stock.

Leave a Comment

Your email address will not be published. Required fields are marked *

On Key

Related Posts

5 Lithium Stocks with High Future Potential

Demand for lithium is expected to increase 8-fold by 2030. The world's largest automakers are racing to go green as the global EV boom continues.


We have collated a list of top five lithium stocks which are well positioned to benefit from the 2023 lithium boom because of their focus on multiple high-potential lithium projects.

100% free. stop anytime no spam